ECG AI-Guided Screening for Low Ejection Fraction

Not Applicable

Completed

• Conditions: Asymptomatic Left Ventricular Systolic Dysfunction (Disorder); Heart Failure

• Registration Number: NCT04000087
• Lead Sponsor: Mayo Clinic

Brief Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of left ventricular systolic dysfunction.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-06-24
• Study First Submitted QC: 2019-06-25
• Study Start: 2019-06-26
• Study First Posted: 2019-06-27
• Primary Completion: 2020-03-31
• Study Completion: 2020-11-01
• Status Verified: 2023-05
• Last Update Submitted: 2023-05-30
• Last Update Posted: 2023-05-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 358

Inclusion Criteria

• Primary care clinicians who are part of a participating care team that care for adult patients and have the ability to order ECG and TTE (this includes physicians, nurse practitioners, and physician assistants).

Exclusion Criteria

• Primary care clinicians working in pediatrics, acute care, nursing homes, and resident care teams.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
New Diagnosis of Low Ejection Fraction (defined as ejection fraction ≤50%)	Within 90 days	Ejection fraction obtained by echocardiography.

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States